Hormonal
Long-term administration of the dual GLP-1/GIP receptor agonist tirzepatide suppresses mammary tumor growth in diet-induced obese mice by reversing metabolic dysregulation and restoring CD8+ T cell function.
For individuals with obesity and hormone-sensitive or obesity-linked cancers, GLP-1/GIP agonists like tirzepatide may offer a dual benefit of weight loss and tumor suppression by correcting metabolic dysregulation. This suggests that treating obesity pharmacologically could be a viable adjunct strategy in oncology, provided lean mass is monitored.
Long-term tirzepatide treatment induced weight loss, mitigated obesity-driven changes in circulating metabolic hormone levels, and suppressed orthotopic E0771 mammary tumor growth.
Why this rating
Preclinical mouse model (DIO + TNBC); not human clinical data.
Source
Tirzepatide restricts obesity-related tumor growth by reversing metabolic dysregulation and rescuing CD8+ T cell function
Elaine M. Glenny et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2024
DOI 10.1101/2024.01.20.576484
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →